Monte Rosa Therapeutics Stock Buy Hold or Sell Recommendation
| GLUE Stock | USD 8.57 0.21 2.51% |
Given the investment horizon of 90 days and your way above-average risk tolerance, our recommendation regarding Monte Rosa Therapeutics is 'Cautious Hold'. Macroaxis provides Monte Rosa buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding GLUE positions.
Check out Monte Rosa Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Monte and provide practical buy, sell, or hold advice based on investors' constraints. Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
Monte |
Execute Monte Rosa Buy or Sell Advice
The Monte recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Monte Rosa Therapeutics. Macroaxis does not own or have any residual interests in Monte Rosa Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Monte Rosa's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Modest | Details | |
Volatility | Unstable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Monte Rosa Trading Alerts and Improvement Suggestions
| Monte Rosa is way too risky over 90 days horizon | |
| Monte Rosa appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (135.35 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Monte Rosa Therapeutics currently holds about 294.14 M in cash with (43.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.32. | |
| Monte Rosa has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Monte Rosa Therapeutics Trading 9 percent Higher Time to Buy |
Monte Rosa current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Monte analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Monte analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Monte Rosa Returns Distribution Density
The distribution of Monte Rosa's historical returns is an attempt to chart the uncertainty of Monte Rosa's future price movements. The chart of the probability distribution of Monte Rosa daily returns describes the distribution of returns around its average expected value. We use Monte Rosa Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Monte Rosa returns is essential to provide solid investment advice for Monte Rosa.
| Mean Return | 1.10 | Value At Risk | -8.29 | Potential Upside | 10.21 | Standard Deviation | 12.73 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Monte Rosa historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Monte Stock Institutional Investors
| Shares | Vestal Point Capital Lp | 2024-06-30 | 890 K | Geode Capital Management, Llc | 2024-06-30 | 847.4 K | State Street Corp | 2024-06-30 | 636.1 K | Exoduspoint Capital Management, Lp | 2024-09-30 | 393.6 K | Sphera Funds Management Ltd. | 2024-06-30 | 375 K | Northern Trust Corp | 2024-09-30 | 358.6 K | Charles Schwab Investment Management Inc | 2024-09-30 | 346.5 K | Renaissance Technologies Corp | 2024-09-30 | 218.7 K | Td Asset Management Inc | 2024-09-30 | 193.7 K | Nea Management Company, Llc | 2024-06-30 | 7.7 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 6 M |
Monte Rosa Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Monte Rosa or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Monte Rosa's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Monte stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.77 | |
β | Beta against Dow Jones | 3.72 | |
σ | Overall volatility | 12.64 | |
Ir | Information ratio | 0.08 |
Monte Rosa Volatility Alert
Monte Rosa Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Monte Rosa's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Monte Rosa's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Monte Rosa Fundamentals Vs Peers
Comparing Monte Rosa's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Monte Rosa's direct or indirect competition across all of the common fundamentals between Monte Rosa and the related equities. This way, we can detect undervalued stocks with similar characteristics as Monte Rosa or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Monte Rosa's fundamental indicators could also be used in its relative valuation, which is a method of valuing Monte Rosa by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Monte Rosa to competition |
| Fundamentals | Monte Rosa | Peer Average |
| Return On Equity | -0.61 | -0.31 |
| Return On Asset | -0.28 | -0.14 |
| Operating Margin | (2.88) % | (5.51) % |
| Current Valuation | 315.12 M | 16.62 B |
| Shares Outstanding | 61.44 M | 571.82 M |
| Shares Owned By Insiders | 0.70 % | 10.09 % |
| Shares Owned By Institutions | 90.66 % | 39.21 % |
| Number Of Shares Shorted | 7.84 M | 4.71 M |
| Price To Earning | 1.91 X | 28.72 X |
| Price To Book | 2.50 X | 9.51 X |
| Price To Sales | 34.30 X | 11.42 X |
| EBITDA | (137.09 M) | 3.9 B |
| Net Income | (135.35 M) | 570.98 M |
| Cash And Equivalents | 294.14 M | 2.7 B |
| Cash Per Share | 6.32 X | 5.01 X |
| Total Debt | 46.04 M | 5.32 B |
| Debt To Equity | 0.16 % | 48.70 % |
| Current Ratio | 20.11 X | 2.16 X |
| Book Value Per Share | 3.35 X | 1.93 K |
| Cash Flow From Operations | (43.8 M) | 971.22 M |
| Short Ratio | 1.65 X | 4.00 X |
| Earnings Per Share | (1.78) X | 3.12 X |
| Target Price | 16.43 | |
| Number Of Employees | 133 | 18.84 K |
| Beta | 1.3 | -0.15 |
| Market Capitalization | 513.61 M | 19.03 B |
| Total Asset | 303.75 M | 29.47 B |
| Retained Earnings | (365.89 M) | 9.33 B |
| Working Capital | 189.62 M | 1.48 B |
| Net Asset | 303.75 M |
Note: Acquisition by Janku Filip of 121000 shares of Monte Rosa at 5.71 subject to Rule 16b-3 [view details]
Monte Rosa Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Monte . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Monte Rosa Buy or Sell Advice
When is the right time to buy or sell Monte Rosa Therapeutics? Buying financial instruments such as Monte Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Monte Rosa in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Buywrite ETFs Thematic Idea Now
Buywrite ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Buywrite ETFs theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Buywrite ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Monte Rosa Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Revenue Per Share 0.221 | Return On Assets (0.28) | Return On Equity (0.61) |
The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.